Posted by: Audrey Erbes | November 17, 2010

Intensive Bioscience Biz Dev Discount Ends Nov. 18

Don’t want you to miss out on discount for the upcoming Dec. 2-3 Bioscience Business Development: Building Value course at UCSC Extension in Santa Clara. The discount ends prior to midnight Nov. 18th. This course which focuses on providing you skills needed to do licensing and deals has been running for 9 years in the Bay Area. It was the first of its kind to provide applied executive training to bioscience industry professionals across all sectors of the industry.

There are two-days of intensive classroom work with 7 speakers followed by two months of mentored term assignment development, latter for those who want credit for the course. Students will have access to BioCentury Archives and Deloitte databases during the term as well as introduction to pages of sources for research and analysis.

Details about course focus, instructors and guest expert speakers appear below:

Bioscience Business Development: Building Value, Thursday and Friday, Dec. 2-3, 2010

Intensive Course: Bioscience Business Development: Building Value, Thursday and Friday, Dec. 2-3, 2010 (2 days of classroom and 2 months to complete project guided by instructor)

Instructors: Audrey S. Erbes, Ph.D., Principal, Erbes & Associates and www.audreysnetwork.comand and Gilbert R. Mintz, Ph.D., President of GRM Associates

Expert Guest Speakers:

§         Harold (Hal) Etterman, MBA, Business Strategist

§         Carolyn Feamster, MBA, VP, Business Strategy & Analysis

§         Ginger R. Dreger, M.S.,  J.D., Arnold & Porter LLP

§         Herwig von Morze, Ph.D., International IP Consultant

§         Tom Gutshall, Chairman & Co-Founder of Cepheid

§         Michael G. McCully, M.S., Director, Recombinant Capital

Please see for details

Date & Time: Dec. 2-3, 2010, Thursday and Friday, 8:30am-5pm

Location: UCSC Extension in Silicon Valley, 2505 Augustine Drive, Santa Clara, CA 95053

Fee: $850; $765 through Nov. 18

Whether financing startup activities, trying to keep pace with the current burn rate, or moving a product into the marketplace, bioscience companies, both large and small, have a critical need for business development at every stage of their evolution.

This course provides an understanding of the critical roles that business development and licensing play in the commercialization of a new product and the development of a successful bioscience company. Through lectures and case studies, participants learn the importance of well-executed opportunity assessments, the hallmarks of viable business models and strategies, and the key financial vehicles for funding and maintaining companies.

The instructors and expert guest speakers offer insight into the importance of strategic deals in building value in bioscience companies. They discuss how to select and target potential partners; assess risks and current trends; determine value and when to deal; and maintain patent integrity worldwide. Finally, the instructors examine the deal-execution process, including negotiating terms, reaching agreement and developing the contract provisions.

Marketing, business development, legal and scientific professionals working in the bioscience arena as well as potential entrepreneurs will benefit from this interactive course.

Topics Include:


AUDREY ERBES, Ph.D., Principal, Erbes & Associates, is a marketing professional with more than 25 years of managerial experience in marketing and business development in the biotech and pharmaceutical industries. She was Executive VP and cofounder of Kowa Research Institute, a biopharmaceutical licensing and investment subsidiary of Kowa Company Ltd., Japan. Previously, she held man­agement positions at Syntex Corp. in market research, product management, strategic marketing and planning, and business development in the U.S. and abroad, with a special emphasis on Europe and Asia/Pacific/Canada. Topic: “Business Development in the Bioscience Industry.”
GILBERT R. MINTZ, Ph.D., is president/owner of GRM Associates, a biotechnology consulting firm with expertise in business development, licensing and strategic planning. With more than 25 years in the biotechnology industry, Dr. Mintz has held corporate management and executive-level business development positions at Genelabs Technologies, Anergen (Corixa), and Cygnus. He has executed technology-platform, corporate and academic collaborations and in/out licensing of late-stage products for partnerships in the U.S., Europe and Japan for such companies as Affymetrix, Aclara and Biota Holdings, Ltd, Facet Biotech. Topic: “Working Your Way Through the Bioscience Licensing Process: Licensing – The Process and Transaction.”


Guest Speakers:

Ginger Dreger, J.D., M.S., partner in Arnold & Porter LLP’s intellectual property practice group, concentrates her practice on counseling and providing strategic advice to emerging and established public companies in the biotechnology, medical device, and pharmaceutical industries. Topic: “What you Need to Know about Patents Working in Business Development.”

Harold (Hal) Etterman, M.B.A., has over 25 years of experience in Finance, Operations and Information Technology, including over ten years serving as a CFO, COO and interim CEO. Hal supports early-stage technology businesses in formulating business strategies, venture funding and the development of strategic alliances. Topic:  “Financial Planning and Funding for a Bioscience Venture: New, Emerging and Growing Entities.”

Carolyn Feamster, M.B.A., a business strategy and analysis consultant, has over 25 years of experience in the pharmaceutical and biotech arenas including therapeutics, diagnostics and drug delivery systems. She has broad expertise across numerous therapeutic areas and has held positions at Syntex, ALZA, Corixa Corporation, and Clearview Projects, where she was most recently vice president of business strategy and analysis. Topic: “Preparing for and Planning Deals for Maximum Strategic Impact.”

Thomas L. Gutshall, chairman as well as co-founder of Cepheid in 1996, was the company’s first CEO. He also served as president and COO for CV Therapeutics from 1994 to 1996. Previously, he was the executive vice president for Syntex Corporation and a member of its pharmaceutical executive committee. Topic: “Cepheid: Business Model, Strategy, Plan and Implementation.”

Mark Edwards, Managing Director, Deloitte Recap, LLC, and Founder, Recombinant Capital has 25 years of experience assisting biotechnology and pharmaceutical clients with negotiation and execution of corporate transactions. He has led or participated directly in many of the breakthrough alliance negotiations over the history of the biotechnology industry. He has been an expert witness in litigations involving billion dollar pharmaceutical franchises. He has opined on reasonable royalties, custom and practice in pharmaceutical licensing, and transfer pricing. As the founder and leader of the Deloitte Recap team, Mark has been responsible for Recap’s coverage, analysis, and insights on biotechnology industry trends and strategies over the past two decades.

In 2008, Mark was awarded a Lifetime Achievement Award by the American Liver Foundation for two decades of leadership, thoughtful insights and detailed analysis of the biotechnology industry.Topic: “BioPharma Alliances: Trends in the Marketplace.”

Herwig von Morzé, Ph.D. is an international patent consultant and has been a patent practitioner since 1968, first in Europe and as of 1974 in the United States. After 21 years in Syntex Patent Department and 8 years at the law firm Heller Ehrman, he founded his own international patent consultant firm in 2004.Topic: “What you Need to Know about Patents Working in Business Development.”


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: